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Forty per cent of HIV-infected children die before they 
reach their first year of life, mainly in the first 6 months. 
Data from the Children with HIV Early Antiretroviral 
Therapy (CHER) study indicate that even when infants 
appear well and their CD4 counts are >25% there is 
a 75% increased risk of mortality when antiretroviral 
therapy (ART) is deferred until threshold CD4 depletion 
occurs or clinical criteria are met.1 Even after starting 
ART, young infants have excess mortality within the first 
year of life. Every effort should therefore be made to 
identify HIV-infected infants as early as possible so that 
ART can be initiated without delay. 
EARLY DIAGNOSIS
Owing to the high prevalence of HIV in southern Africa, 
the HIV status of all infants (and their mothers) access-
ing any health care facility (including consulting rooms 
of family practitioners, immunisation clinics, hospitals, 
etc.) for any reason should be determined.
n  Mother known to be HIV positive, infant’s status un-
known – DNA PCR testing for infant as early as pos-
sible. 
n  Mother’s HIV status unknown – rapid HIV test for 
mother or for infant if mother unavailable, followed 
by a DNA PCR for infant if either rapid test is posi-
tive.
n  Mother HIV negative during pregnancy – offer repeat 
rapid HIV testing for mother and/or infant. If either is 
positive, then DNA PCR testing for infant.
All HIV-positive mothers should have a CD4 count done 
and be referred urgently for care if the CD4 count is 
<350 cells/µl. (The Southern African HIV Clinicians So-
ciety recommends initiation of ART in all pregnant HIV-
positive women where resources are available.2) 
Once an HIV diagnosis is made in the infant, ALL HIV-
infected infants should urgently be referred to an ART 
treatment site.
Start all HIV-exposed infants on co-trimoxazole from at 
least 4 - 6 weeks. 
Immunisation should continue as per the Expanded Pro-
gramme on Immunization.
When infants are diagnosed as HIV positive (i.e. by 
polymerase chain reaction (PCR)), mothers should be 
encouraged to continue or re-initiate breast-feeding.
ANTIRETROVIRAL THERAPY
According to recently updated recommendations from 
the World Health Organization (WHO) in June 2008,3 all 
HIV-infected infants <12 months of age must be 
fast-tracked to receive ART.
The interval between identification, adherence counsel-
ling and commencing ART should be as short as possible 
(1 - 2 weeks) as infants deteriorate rapidly. Adherence 
counselling should continue after commencement of 
treatment.
ART can be initiated after the first positive PCR, while 
awaiting confirmatory studies such as plasma HIV RNA 
(usually done at baseline before starting ART). 
Infants diagnosed with HIV infection in hospital should 
be prepared and started on ART before discharge when-
ever possible (i.e. in most cases). 
All infants in South Africa should be started on a com-
bination of:
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n   Stavudine 1 mg/kg/dose bd (abacavir at 8 mg/kg/dose 
bd preferred)
n Lamivudine 4 mg/kg/dose bd
n  Lopinavir/ritonavir (LPV/r) 300 mg/m2/dose bd (the 
WHO recommends LPV/r when NVP is used for pre-
vention of mother-to-child transmission (PMTCT)).
Even when infants start ART early they remain at 
increased risk of illness and death, particularly in 
the first few months. All infants under 12 months 
old, even after starting on ART, should be assessed 
monthly until their first birthday.
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Course Name Course Dates City/town Cost (VAT Incl)
HIV/AIDS Management Course: Given the current state of knowledge on HIV/AIDS management and the fact that
anti-retroviral therapy is becoming more affordable, it is now feasible to approach HIV/AIDS as a chronic medical
condition. This course will empower clinicians to adequately manage patients with HIV and or AIDS.
HIV/AIDS Management Course 27-28 Feb 2009 Cape Town R 3,000.00
HIV/AIDS Management Course 28 -29 March 2009 Durban R 3,000.00
HIV/AIDS Management Course 3-5 April 2009 JHB R 3,000.00
HIV/AIDS Management Course 13-14 June 2009 JHB R 3,000.00
HIV/AIDS Management Course 8-9 Aug 2009 Pretoria R 3,000.00
HIV/AIDS Management Course 25-27 Sept 2009 Cape Town R 3,000.00
HIV/AIDS Management Course 2-4 Oct 2009 Durban R 3,000.00
HIV/AIDS Management Course 9-11 Oct 2009 Free State R 3,000.00
HIV/AIDS Management Course 21-22 Nov 2009 Mpumalanga R 3,000.00
HIV/AIDS Management Course 1-3 Dec 2009 Pta R 3,000.00
HIV/AIDS Management Course 3-5 Dec 2009 Cape Town R 3,000.00
HIV/AIDS Refresher Seminar: HIV/AIDS is an ever-evolving discipline and with ARV drugs becoming more
affordable, health professionals therefore need to stay abreast with the latest developments. The Foundation for
Professional Development, in association with the Southern African HIV Clinician Society, developed this one-day
refresher seminar which is targeted at alumni who successfully completed the 3-Day HIV/AIDS Management Course.
We encourage all our alumni who completed the 3-day course to enrol on this refresher course so that they have
access to the most recent evidence-based information on drugs and the management of HIV/AIDS patients.
HIV/AIDS Refresher Seminar 28-Feb-09 JHB R 1,300.00
HIV/AIDS Refresher Seminar 11-Mar JHB R 1,300.00
HIV/AIDS Refresher Seminar 30-May-09 Durban R 1,300.00
HIV/AIDS Refresher Seminar 5-Nov-09 Cape Town R 1,300.00
HIV/AIDS Refresher Seminar 1-Dec-09 Durban R 1,300.00
Paediatric HIV/AIDS Management Course: Children with HIV/AIDS are dying unnecessarily because of a lack of
access to ARV treatment. The problems arise mainly from a lack of cheap feasible diagnostic tests for children under
18 months, lack of trained health personnel and the affordable child-friendly ARV drugs. Simplified treatment
guidelines coupled with a range of fixed-dose combinations of ARVs that require only one or two pills twice a day
make it easier to treat HIV/AIDS in adults, but development of simplified drugs for children lags behind. Despite WHO
simplified treatment guidelines that specify which drugs to use in children, countries have difficulty in getting simple
and affordable combinations of the drugs. Two generic fixed-dose combinations should enter clinical trails this year,
and there are frighteningly few second-line ARV drugs available for children in countries with large numbers of infected
children.
Paediatric HIV/AIDS Management Course 13-15 March 2009 Pretoria R 3,200.00
Paediatric HIV/AIDS Management Course 27-29 April 2009 CT R 3,200.00
Paediatric HIV/AIDS Management Course 8-10 May 2009 CT R 3,200.00
Paediatric HIV/AIDS Management Course 2-4 Oct 2009 PTA R 3,200.00
Clinical and Ethical Refresher Course for GP's: The Clinical and Ethical Refresher Seminar is designed to offer a
unique learning experience by combining clinical and ethical issues in an effort to help general practitioners to update
their skills and knowledge in specific areas. Most healthcare professionals have limited time available to attend clinical
programmes. Furthermore, attending individual courses is costly and may be time consuming. The FPD Summer
Academy therefore intends to offer healthcare professionals an opportunity to get away, save time and money, gain
CPD points for attending this learning experience and get the best of what FPD has to offer.
Clinical and Ethical Refresher Course for GPs 30/5-1/6 2009 Midrand R 3,140.00
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